ArticlePloS one2016
CDDO-Me Redirects Activation of Breast Tumor Associated Macrophages.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 33 citations in OpenAlex.
- Integrating multi-omics data to identify the role of Aggrephagy-related genes in tumor microenvironment and key tumorigenesis factors of GB from the perspective of single-cell sequencing.Discover oncology · 2025Article
- Nrf2-dependent effects of CDDO-Me on bactericidal activity in macrophage infection models.Frontiers in immunology · 2025Article
- The Triterpenoid CDDO-Methyl Ester Redirects Macrophage Polarization and Reduces Lung Tumor Burden in a Nrf2-Dependent Manner.Antioxidants (Basel, Switzerland) · 2023Article
- Interplay between fat cells and immune cells in bone: Impact on malignant progression and therapeutic response.Pharmacology & therapeutics · 2022Review
- T Cells and CDDO-Me Attenuate Immunosuppressive Activation of Human Melanoma-Conditioned Macrophages.Frontiers in immunology · 2022Article
- Bioactive small-molecule constituents of Lao plants.Journal of medicinal plant research · 2021Article
- The role of tumor-associated macrophages in osteosarcoma progression - therapeutic implications.Cellular oncology (Dordrecht, Netherlands) · 2021Review
- Electrophile Modulation of Inflammation: A Two-Hit Approach.Metabolites · 2020Review
- Dual Effect of Soloxolone Methyl on LPS-Induced Inflammation In Vitro and In Vivo.International journal of molecular sciences · 2020Article
- Current Landscape of NRF2 Biomarkers in Clinical Trials.Antioxidants (Basel, Switzerland) · 2020Review
- Profibrotic Activation of Human Macrophages in Systemic Sclerosis.Arthritis & rheumatology (Hoboken, N.J.) · 2020Article
- Prophylactic and therapeutic roles of oleanolic acid and its derivatives in several diseases.World journal of clinical cases · 2020Review
- CDDO-Me Alters the Tumor Microenvironment in Estrogen Receptor Negative Breast Cancer.Scientific reports · 2020Article
- Synthesis and Anticancer Activity of CDDO and CDDO-Me, Two Derivatives of Natural Triterpenoids.Molecules (Basel, Switzerland) · 2019Review
- Deep insights into the response of human cervical carcinoma cells to a new cyano enone-bearing triterpenoid soloxolone methyl: a transcriptome analysis.Oncotarget · 2019Article
- Natural Product Triterpenoids and Their Semi-Synthetic Derivatives with Potential Anticancer Activity.Planta medica · 2019Review
- Molecular Repolarisation of Tumour-Associated Macrophages.Molecules (Basel, Switzerland) · 2018Review
- Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy.Frontiers in immunology · 2018Review
- The triterpenoid CDDO-imidazolide reduces immune cell infiltration and cytokine secretion in the KrasG12D;Pdx1-Cre (KC) mouse model of pancreatic cancer.Carcinogenesis · 2016Article
- The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9.Nature immunology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Tumor-associated macrophages can account for up to 50% of the tumor mass in breast cancer patients and high TAM density is associated with poor clinical prognosis. Because TAMs enhance tumor growth, development, and metastatic potential, redirection of TAM activation may have significant therapeutic benefit. Our studies in primary human macrophages and murine breast TAMs suggest that the synthetic oleanane triterpenoid CDDO-methyl ester (CDDO-Me) reprograms the activation profile of TAMs from tumor-promoting to tumor-inhibiting. We show that CDDO-Me treatment inhibits expression of IL-10 and VEGF in stimulated human M2 macrophages and TAMs but increases expression of TNF-α and IL-6. Surface expression of CD206 and CD163, which are characteristic of M2 activation, is significantly attenuated by CDDO-Me. In contrast, CDDO-Me up-regulates surface expression of HLA-DR and CD80, which are markers of M1 activation, and importantly potentiates macrophage activation of autologous T cells but inhibits endothelial cell vascularization. These results show for the first time that CDDO-Me redirects activation of M2 macrophages and TAMs from immune-suppressive to immune-stimulatory, and implicate a role for CDDO-Me as an immunotherapeutic in the treatment of breast and potentially other types of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.